Covadonga Paneda
Chief Operating Officer Altamira Therapeutics
Covadonga Pañeda holds a Msc. and Ph.D. in Biochemistry and Molecular Biology from Madrid’s Universidad Autónoma and a Master in Biotech Management by Fundación Genoma España. After 4 years as a postdoc at Scripps Research Institute, La Jolla, CA, she moved to industry where she has accumulated a broad experience in biotech leadership and management. Before joining Altamira in 2022, she spent seven years managing Sylentis’ R&D efforts, two years leading the translational activities of several start-up companies, including Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a neuroimmune biopharmaceutical company.
Seminars
Friday 19th February 2027
Advancing Extrahepatic RNA Delivery Through Modular Peptide-Based Nanoparticles for Emerging Therapeutic Applications
8:45 am
- Enabling extrahepatic delivery to the tumour microenvironment using peptide-based nanoparticles
- Optimising the modularity and flexibility of peptide-based delivery systems to improve tissue selectivity and expand targeting capabilities
- Evaluating emerging oncology applications of non-viral delivery platforms, including preclinical approaches to assessing therapeutic performance and tissue distribution
